Omalizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase III for Asthma. According to GlobalData, Phase III drugs for Asthma have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Omalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omalizumab biosimilar overview
Omalizumab biosimilar (BP-11) is under development for the treatment of asthma, allergic asthma, chronic spontaneous urticaria, chronic idiopathic urticaria (CIU) and nasal polyps. It is administered through subcutaneous route as powder for solution. The drug candidate acts by targeting human immunoglobulin E (IgE).
Curateq Biologics overview
Curateq Biologics, a subsidiary of Aurobindo Pharma Ltd, is engaged in the research and development of recombinant biologics, especially in areas of biosimilars drug substance development and proteins formulations. Curateq Biologics is headquartered in Hyderabad, Telangana, India.
For a complete picture of Omalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.